Histone Acetylation and Its Modifiers in the Pathogenesis of Diabetic Nephropathy

Abstract EN

Diabetic nephropathy (DN) remains a leading cause of mortality worldwide despite advances in its prevention and management.

A comprehensive understanding of factors contributing to DN is required to develop more effective therapeutic options.

It is becoming more evident that histone acetylation (HAc), as one of the epigenetic mechanisms, is thought to be associated with the etiology of diabetic vascular complications such as diabetic retinopathy (DR), diabetic cardiomyopathy (DCM), and DN.

Histone acetylases (HATs) and histone deacetylases (HDACs) are the well-known regulators of reversible acetylation in the amino-terminal domains of histone and nonhistone proteins.

In DN, however, the roles of histone acetylation (HAc) and these enzymes are still controversial.

Some new evidence has revealed that HATs and HDACs inhibitors are renoprotective in cellular and animal models of DN, while, on the other hand, upregulation of HAc has been implicated in the pathogenesis of DN.

In this review, we focus on the recent advances on the roles of HAc and their covalent enzymes in the development and progression of DN in certain cellular processes including fibrosis, inflammation, hypertrophy, and oxidative stress and discuss how targeting these enzymes and their inhibitors can ultimately lead to the therapeutic approaches for treating DN.